What is Aphea.Bio?
Founded in 2017 and headquartered in Zwijnaarde, Belgium, Aphea.Bio operates at the intersection of microbiology and crop science. The company specializes in developing novel biological products designed to optimize agricultural productivity while minimizing environmental impact. By focusing on the reduction of synthetic fertilizer application and the mitigation of fungal diseases, pests, and weeds, Aphea.Bio provides a robust framework for the future of sustainable farming. Its market position is defined by a commitment to creating a reliable and profitable food chain, leveraging proprietary microbial technologies to meet the increasing demand for eco-friendly agricultural inputs in a resource-constrained world.
How much funding has Aphea.Bio raised?
Aphea.Bio has raised a total of $105.5M across 3 funding rounds:
Series A
$10.9M
Series B
$16.8M
Series C
$77.8M
Series A (2017): $10.9M with participation from Agri Investment Fund scrl, Vives Louvain Technology Fund, Qbic II, V-Bio Ventures, and PMV
Series B (2020): $16.8M led by Astanor Ventures, PMV nv, V-Bio Ventures, Vives, and Agri Investment Fund scrl
Series C (2023): $77.8M supported by BNP Paribas, Bill & Melinda Gates Foundation, and Innovation Industries
Key Investors in Aphea.Bio
BNP Paribas
A leading international banking group providing comprehensive corporate and institutional banking services, with a strong commitment to sustainable finance and energy transition projects.
Bill & Melinda Gates Foundation
A global philanthropic organization focused on improving healthcare and reducing extreme poverty, with a specific interest in agricultural innovation to support food security.
V-Bio Ventures
A specialized life science venture capital firm that co-creates and invests in early- to mid-stage companies with high growth potential and differentiated technologies.
What's next for Aphea.Bio?
With the successful completion of its latest funding round, Aphea.Bio is well-positioned to scale its commercial operations and expand its product pipeline. The strategic focus will likely shift toward accelerating the market penetration of its existing biological solutions and investing in the R&D required to address emerging agricultural threats. As the company matures, it will continue to leverage its strong institutional partnerships to navigate the complexities of global regulatory environments and supply chain integration, ensuring that its innovative technologies reach a broader international market. The current trajectory suggests a sustained emphasis on long-term growth and the solidification of its role as a leader in the global AgTech ecosystem.
See full Aphea.Bio company page
